Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) announced it is buying DiagnaMed Holdings Corp.’s (CSE: DMED) (OTCQB: DGNMF) intellectual property on molecular hydrogen as potential treatments for neurological and mental health disorders. Revive told investors it entered into a non-binding letter of intent dated February 28, 2025 and is expected…
Please login to read all 429 words.
